Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKUPW0)

Drug Name

ABX-0401 Drug Info

Synonyms

ALX-0071; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Pfizer; Nanobody therapeutics (inflammation/rheumatoid arthritis/inflammatory bowel disease), Ablynx/Wyeth

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Preclinical	[1]

Cross-matching ID

TTD Drug ID: DMKUPW0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[3]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[4]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[5]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[6]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[7]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[8]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[9]
Etanercept	DMCV109	Arthritis	FA20	Approved	[10]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[11]
Infliximab	DMH7OIA	Crohn disease	DD70	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020354)
2	US patent application no. 8007,790, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases.
3	Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
4	Clinical pipeline report, company report or official report of AstraZeneca (2009).
5	Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
6	Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
7	Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
8	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
9	Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
10	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
11	Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
12	Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.